



February 4, 2015

PDL BioPharma to Present at Upcoming Investor Conferences

INCLINE VILLAGE, Nev., Feb. 4, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences.

2015 BIO CEO & Investor Conference

Monday, February 9, 2015
2:00 p.m. EST
New York, NY

2015 RBC Capital Markets' Global Healthcare Conference

Wednesday, February 25, 2015
9:30 a.m. EST
New York, NY

Cowen and Company 35th Annual Health Care Conference

Wednesday, March 4, 2015
8:40 a.m. EST
Boston, MA

To access the live and subsequently archived webcasts of the presentations, go to the Company's website at <http://www.pdl.com> and go to "Events and Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. The archived webcast will be available for seven days following each presentation.

About PDL BioPharma

PDL manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has invested approximately \$780 million to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its shareholders.

The Company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue.

For more information, please visit www.pdl.com.

PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Logo - <http://photos.prnewswire.com/prnh/20110822/SF55808LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/pdl-biopharma-to-present-at-upcoming-investor-conferences-300030584.html>

SOURCE PDL BioPharma, Inc.

News Provided by Acquire Media